Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Samuels Replaces Smith As BGMA Chief

Warwick Smith Steps Down After 25 Years As Head Of UK Association

Executive Summary

Warwick Smith has stepped down as head of the British Generic Manufacturers Association and British Biosimilars Association, to be replaced by Mark Samuels as CEO.

You may also be interested in...



New BGMA Chief Battles Twin Pressures Of COVID And Brexit

When Mark Samuels took over leadership of the BGMA earlier this year, he was immediately forced to grapple with the twin pressures of Brexit and the COVID-19 pandemic. However, he tells Generics Bulletin in an exclusive interview, the UK off-patent industry has succeeded in maintaining supply against this difficult backdrop and deserves a more coherent government strategy to support the sector.

UK Could Become ‘World Leader’ On Biosimilar Regulation

The UK is putting itself in a position to play a leading role in global biosimilars regulation, thanks to a proposed new registration pathway that will not require comparative efficacy data, delegates to a Westminster Health Forum online conference heard.

UK Could Become ‘World Leader’ On Biosimilar Regulation

The UK is putting itself in a position to play a leading role in global biosimilars regulation, thanks to a proposed new registration pathway that will not require comparative efficacy data, delegates to a Westminster Health Forum online conference heard earlier today.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

GB150677

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel